Schistosomiasis, caused by trematode flatworms of the genus *Schistosoma,* is a debilitating and serious parasitic neglected tropical disease (NTD) that leads to chronic ill-health.^[@ref20]^ There are two major forms of schistosomiasis infections, urogenital and intestinal. Urogenital schistosomiasis is caused by *S. hematobium*, and intestinal schistosomiasis is caused by *S. mansoni*, *S. japonicum*, *S. mekongi*, and *S. guineensis* (and related *S. intercalatum*).^[@ref20]^ The disease is currently treated and controlled with praziquantel; estimates show that at least 74 million people required treatment, and an additional 220 million people received prophylactic treatment in 2017.^[@ref20]^ Praziquantel is currently used against all *Schistosoma* species, but due to increasing concerns of resistance and inadequate efficacy there is a need for new therapeutics.^[@ref2]^ To shorten the timeline and costs associated with developing drugs against NTDs, repurposing efforts utilizing known drugs as starting points for chemical exploration and development can be employed.^[@ref3]^

A target class repurposing approach was undertaken in order to optimize the U.S. Food and Drug Administration-approved drug lapatinib (Tykerb) (**1**) as an antitrypanosomal drug against *Trypanosoma brucei brucei* ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref4]^ A series of lapatinib-derived analogs were produced during medicinal chemistry optimization campaigns,^[@ref5]−[@ref8]^ ultimately resulting in the discovery of **3** (**NEU-1953**),^[@ref8]^ a compound that displayed moderate antitrypanosomal potency.^[@ref9]^ Subsequent efforts focused on the solubility-driven optimization of **3**, while maintaining its antitrypanosomal potency and selectivity.^[@ref10]^

![Target class repurposing of lapatinib as an antitrypanosomal compound.^[@ref4]−[@ref9]^ The different regions of exploration around **3** are denoted by color (head region is red; tail region is green; core is blue).](ml9b00455_0001){#fig1}

Historically, we have cross-screened compounds arising from our different kinase inhibitor repurposing projects against various parasites,^[@ref5],[@ref9],[@ref11],[@ref12]^ and due to the known representation of protein kinases in *S. mansoni*,^[@ref13]^ a subset of the compounds from this optimization campaign was screened against the parasite. [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} summarizes a set of desired properties for antischistosomal lead compounds that are based on a suggested target product profile for schistosomiasis^[@ref2],[@ref14],[@ref15]^ and its emphasis on oral bioavailability. The *in vitro* ADME properties that are described were designed in-house with oral bioavailability in mind.

###### Targeted *in Vitro* and *in Vivo* Properties for Antischistosomal Lead Compounds

                                                      property                            suggested minimum value or threshold
  --------------------------------------------------- ----------------------------------- ------------------------------------------
  *in vitro* bioactivity and selectivity properties   *S. mansoni* severity score         at 10 μM ≥ 2 after 5 h or ≥ 3 after 24 h
  HepG2 TC~50~                                        ≥ 5 μM after 48 h                   
  *in vitro* ADME properties                          human liver microsome clearance     Cl~int~ \< 8.6 μL/min/mg protein
  rat hepatocyte clearance                            Cl~int~ \< 5.1 μL/min/10^6^ cells   
  plasma protein binding (PPB)                        \< 95%                              
  thermodynamic solubility (pH = 7)                   \> 100 μM                           

Because the schistosome parasite can present multiple and dynamic phenotypic responses to chemical insult,^[@ref16]^ we employ a constrained nomenclature of descriptors to describe the changes in the parasite as a function of time and concentration (*e.g*., motility, density, and shape; and in the case of the adult parasite, an inability to adhere to the bottom of the assay dish). These descriptors are converted into severity scores on a scale of 0 (green)--4 (severest/red) that allow for partially quantitative comparisons of compound effects.^[@ref1]−[@ref19]^ Preference is given to those compounds that generate the highest severity score in the least time on the basis that highly active acute (single dose) therapies are part of the profile associated with a new drug to treat schistosomiasis.^[@ref2],[@ref14],[@ref15]^ The descriptors themselves and their respective scores are detailed in the [Supporting Information, Table S1](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00455/suppl_file/ml9b00455_si_001.pdf). Severity score data are presented in the results (with the corresponding descriptors detailed in the [Supporting Information, Tables S2--S8](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00455/suppl_file/ml9b00455_si_001.pdf)), and eight new analogs developed and synthesized in support of this effort are described. Finally, absorption, distribution, metabolism and excretion (ADME) data of all compounds presented in this work are reported in the [Supporting Information, Table S15](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00455/suppl_file/ml9b00455_si_001.pdf).

When screened against adult *S. mansoni*, **3** displayed no bioactivity, which was also observed of the *tert*-butyl carbamate synthetic precursor **3a** and a methylene carboxylic acid **3b** ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). Replacement of the piperazine with proline **3c** maintains no bioactivity; however, its methyl ester derivative **3d** displayed bioactivity after 24 h, progressing to the severest response by 48 h. This result may be due to the compound being a more cell-permeable pro-drug of **3c**. Compound **3e**, possessing a *tert*-butyl carbamate methylethylenediamine in place of the piperazine, displays a maximal phenotypic response after 48 h though this was also accompanied by an increase in toxicity versus HepG2 cells; however, both **3d** and **3e** display poor ADME profiles overall (see [Supporting Information, Table S15](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00455/suppl_file/ml9b00455_si_001.pdf)).

###### Phenotypic Changes, Expressed as Severity Scores, in *S. mansoni* and HepG2 TC~50~ for Piperazine-Replacement Analogs **3a**--**3e**
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Introduction of the bridged piperazine **4a** improved aqueous solubility and metabolic stability in comparison to **3**, though minimal bioactivity was observed after 48 h ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}). Extending the length of the piperazine alkyl chain to the ethyl (**4b**) and propyl (**4c**) resulted in activity after 5 h in both cases, with the propyl possessing the most severe phenotypic response after 48 h. Substitution of the piperazine for the *N-*alkylhomopiperazine derivatives (**4d**--**f**), and the unsubstituted homopiperazine (**4g**) (synthesis detailed in [Supporting Information, Scheme S1](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00455/suppl_file/ml9b00455_si_001.pdf)), improved the solubility of the compounds in comparison to **3**. However, bioactivity of this series was not observed against adult schistosomes.

###### Phenotypic Changes, Expressed as Severity Scores, in *S. mansoni* and HepG2 TC~50~ for Piperazine-Replacement, Increasing sp^3^ Carbon Content, Analogs **4a**--**4g**
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Replacing the 2-aminopyrazine headgroup of **3** with saturated rings ([Supporting Information, Table S4](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00455/suppl_file/ml9b00455_si_001.pdf)) resulted in no significant bioactivity recorded for tertiary amines (**S1a** and **S1b**) or upon replacement of the 2-aminopyrazine with either a cyclohexanol (**S1c**), tetrahydropyran (**S1d**), or methylene tetrahydropyran (**S1e**). Overall, it was noted that while increasing the sp^3^ content of the headgroup did achieve improved aqueous solubility in comparison to **3**, these analogs displayed variable toxicity against HepG2 cells.

Notably, methylation at the 5-position of the 2-aminopyrazine headgroup (**5a**) resulted in a severe phenotypic response after just 5 h, vastly different from the negligible bioactivity observed of **3** ([Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}). However, aqueous solubility and metabolic stability decreased, and toxicity against HepG2 cells increased greater than 1.9-fold. The *N-*methylhomopiperazine tail counterpart, **5b**, provided a potent compound with bioactivity recorded after 24 h, a later time point than **5a**. Although **5a** was a more potent antischistosomal lead, **5b** displayed a superior ADME profile. The unsubstituted 2-aminopyrazine and pyrimidine headgroup analogs (**4d** and **5c**, respectively) led to a complete loss in activity, whereas replacement with 3-chloro-4-methoxyphenyl (**5d**) (a truncated version of the lapatinib (**1**) headgroup) generated severe phenotypic responses, albeit it with a 7-fold decrease in aqueous solubility when compared to **3** and an undesirable ADME and selectivity profile. Replacement of the tail group of **5d** with a phenyl sulfonamide, *N*-methylhomopiperazine (**5e**), yielded a complete loss of bioactivity. However, maintaining this phenyl sulfonamide, *N*-methylhomopiperazine tail in the presence of a 3-chloropyridine headgroup (**5f**) resulted in moderate bioactivity recorded after 1 h, which remained consistent over time. In line with the structure--activity relationships (SAR) observed with respect to substitution on the headgroup (compounds **5a**, **5b**, **5d**), the presence of a substituent at the *para* position of the headgroup appears to increase potency of the compounds, and the presence of the nitrogen within the ring appears to be beneficial for potent activity. However, **5f** exhibited poor aqueous solubility and was rapidly cleared in human liver microsomes (HLM) as well as being toxic to HepG2 cells (TC~50~ 1.8 μM). Analogs were tested that investigated headgroup replacements, including saturated groups matched with various tails, although this time at the 6-position of the core ([Supporting Information, Table S11](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00455/suppl_file/ml9b00455_si_001.pdf)). No notable activity against schistosomes was recorded, with the exception of compound **S3b** (pyrimidine headgroup in combination with a phenyl sulfonyl morpholine tail at the 6-position), which displayed moderate activity after 1 h.

###### Phenotypic Changes, Expressed as Severity Scores, in *S. mansoni* and HepG2 TC~50~ for 2-Aminopyrazine Headgroup Replacement Analogs **5a**--**5f**
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Isocryptolepine analogs were tested ([Table [5](#tbl5){ref-type="other"}](#tbl5){ref-type="other"}), initially possessing an unsubstituted headgroup (R^1^ = H), and the tail group was modified from a phenylmorpholine of **6a** to the pyrimidine *N*-methylhomopiperazine of **6b**, which both showed minimal bioactivity after 5 h, with **6b** displaying potent activity after 48 h. Maintaining the pyrimidine *N-*methylhomopiperazine tail, methylation of the R^1^ position (**6c**), resulted in severe bioactivity after 1 h. This result is in line with SAR trends observed previously where substitution on the headgroup appears to be beneficial to antischistosomal potency. However, **6c** displayed undesirable toxicity against HepG2 cells.

###### Phenotypic Changes, Expressed as Severity Scores, in *S. mansoni* and HepG2 TC~50~ for Isocryptolepine Analogs **6a**--**6c**
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Pseudoring analogs matched to the bioactive **5d**, possessing the 2-chloro-4-methoxy headgroup and varying tail groups, are presented in [Table [6](#tbl6){ref-type="other"}](#tbl6){ref-type="other"}. The direct pseudoring matched pair (**7b**) showed minimal bioactivity after 5 h and potent activity after 48 h. Replacement of the *N-*methylhomopiperazine to the *N-*methylpiperazine tail (**7a**) resulted in a complete loss of activity. Further, replacement of the tail with the phenylsulfonamide *N-*methylpiperazine (**7c**) produced a phenotypic response after 5 h. The *meta*-substituted phenylmorpholine (**7d**) displayed a phenotypic response after 1 h which increased in severity over time. Replacement of the −OH functionality of **7d** with the free amine yielded **7e**, a compound that was not as potent as its counterpart but displayed bioactivity after 24 h nonetheless. In general, this series displayed poor aqueous solubility. Additional pseudoring analogs were explored with alternate head and tail group variations; however, there was no notable activity reported ([Supporting Information, Table S13](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00455/suppl_file/ml9b00455_si_001.pdf)).

###### Phenotypic Changes, Expressed as Severity Scores, in *S. mansoni* and HepG2 TC~50~ for Pseudoring Analogs **7a**--**7e**[a](#t6fn1){ref-type="table-fn"}
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nt = not tested.

*Ortho-*methylated core analogs were screened against *S. mansoni*, and the severity scores are presented in [Table [7](#tbl7){ref-type="other"}](#tbl7){ref-type="other"} with the ADME data of the series subsequently presented in [Table [8](#tbl8){ref-type="other"}](#tbl8){ref-type="other"}. Installation of a methyl at the 6-position of the quinoline core (**8a**) resulted in a compound that showed a severe phenotypic response by 5 h that subsequently increased over time. However, this compound also exhibited a greater than 5-fold increase in toxicity against HepG2 cells and a \>2200-fold decrease in aqueous solubility compared with **3**. Alternatively, methylation at the 8-position of the quinoline (**9a**) provided a compound with moderate potency after 24 h; however, it exhibited poor physicochemical properties and toxicity against HepG2 cells. In an attempt to optimize the series, additional *ortho*-methylated analogs were designed to improve the antischistosomal activity and to exploit functionality that would improve the ADME and toxicity profile. We had already shown that replacement of the piperazine with a homopiperazine improved the ADME profile;^[@ref10]^ as such, we substituted the piperazine for the homopiperazine and explored the effect of the length and presence of the alkyl chain.

###### Phenotypic Changes, Expressed as Severity Scores, in *S. mansoni* and HepG2 TC~50~ for *ortho*-Methylated Analogs **8a**--**8e** and **9a**--**9e**[a](#t7fn1){ref-type="table-fn"}
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nt = not tested.

###### ADME Profile, Including Aqueous Solubility, Plasma Protein Binding, and Metabolic Stability, of *ortho*-Methylated Quinoline Analogs

  ID                       aq sol[a](#t8fn1){ref-type="table-fn"} (μM)   human PPB[b](#t8fn2){ref-type="table-fn"} (%)   HLM[c](#t8fn3){ref-type="table-fn"} Cl~int~[d](#t8fn4){ref-type="table-fn"} (μL/min/mg protein)
  ------------------------ --------------------------------------------- ----------------------------------------------- -------------------------------------------------------------------------------------------------
  **3**([@ref8],[@ref9])   44                                            87                                              180
  **8a**([@ref10])         \< 0.02                                       97                                              130
  **8b**                   670                                           82                                              260
  **8c**                   790                                           84                                              300
  **8d**                   480                                           88                                              300
  **8e**                   1000                                          70                                              13
  **9a**([@ref10])         5.0                                           97                                              120
  **9b**                   860                                           82                                              120
  **9c**                   580                                           88                                              160
  **9d**                   450                                           94                                              300
  **9e**                   465                                           76                                              41

aq sol = aqueous solubility.

PPB = plasma protein binding.

HLM = human liver microsomes.

Cl~int~ = intrinsic clearance.

A general synthetic scheme that closely follows one we previously reported^[@ref10]^ for novel *ortho*-methylated analogs is presented in the [Supporting Information (Scheme S2)](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00455/suppl_file/ml9b00455_si_001.pdf).

Focusing on the 6-methyl core, replacement of the piperazine with the *N-*methylhomopiperazine (**8b**) resulted in the most potent compound to date, with a severe phenotypic response recorded after 1 h. Extension of the alkyl chain to an ethyl (**8c**) provided a similar phenotypic response, further extension to a propyl (**8d**) resulted in bioactivity being detected after 1 h, and a more severe phenotypic response was recorded after 24 h. These compounds showed the greatest antischistosomal activity of the series, with **8b** possessing \>33,500-fold improvement in solubility compared to **8a**; however, clearance increased 2-fold, and no toxicity improvement was observed. The unsubstituted homopiperazine (**8e**) improved metabolic stability 10-fold in comparison to **8a** and was modestly less toxic, though the compound was inactive against schistosomes.

The 8-methyl core was then explored. Although appreciably soluble, replacement of the *N*-methylpiperazine for the *N*-methylhomopiperazine (**9b**) and subsequent extension to the *N*-ethylhomopiperazine (**9c**) resulted in compounds that showed no bioactivity. Further extension of the alkyl chain improved potency, with the *N-*propylhomopiperazine (**9d**) strongly bioactive by 24 h. Unfortunately, this was accompanied by high HLM clearance and concerns with toxicity against HepG2 cells. Interestingly, the unsubstituted homopiperazine (**9e**) led to an analog with a phenotypic response after 5 h, which was not observed in its 6-methylated quinoline counterpart **8e**. Analog **9e** also exhibited improved metabolic stability.

A series of compounds designed to improve the physicochemical profile of an antitrypanosomal lead compound, **NEU-1953** (**3**), were crossed-screened against adult *S. mansoni*. Four potent compounds of interest (**5a**, **5d**, **6c**, and **8a**) were identified, with the most promising possessing an *ortho*-methylated quinoline core. Compounds of this series were further explored, optimizing for antischistosomal activity, which resulted in **8b**--a promising lead--with **8a**, **8c**, and **9e** presenting as potential backup leads for further assessment and optimization as antischistosomal compounds.

The Supporting Information is available free of charge at [https://pubs.acs.org/doi/10.1021/acsmedchemlett.9b00455](https://pubs.acs.org/doi/10.1021/acsmedchemlett.9b00455?goto=supporting-info).Details of biological assay protocols, chemistry experimental, *in vitro* ADME properties, and additional supplementary data ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsmedchemlett.9b00455/suppl_file/ml9b00455_si_001.pdf))
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